Keyword Tag Sort by

Neuroendocrine tumors News (3 articles)



Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors

Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary endpoint of progression-free survival[1] Analyses to adjust for imbalances in...

Published on 11 October 2010, 08:28


Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients

Everolimus extended median progression-free survival from 4.6 to 11.0 months vs. placebo and reduced risk of cancer progression by 65%[1] Patients with advanced pancreatic neuroendocrine tumors (NET) have a rare and aggressive form of cancer with limited treatment options[2,3]...

Published on 1 July 2010, 12:15


Pivotal Phase III trial of Novartis drug Afinitor® met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors

RADIANT-3 study results show everolimus significantly extends progression-free survival in patients with advanced pancreatic neuroendocrine tumors (NET) Patients with advanced pancreatic NET have a rare and aggressive form of cancer with limited treatment options[1],[2]...

Published on 3 June 2010, 02:50


image